These findings also identify cdkn2b as an epigenetic target of EZH2, and provide the rationale for launching clinical trials of EZH2 inhibitors in relapsed or treatment refractory mantle cell lymphoma patients or other B-cell malignancies. Here, CDKN2B is linked to mantle cell lymphoma.